Teijin Pharma

Teijin Pharma, Amgen collaborate for autoimmune diseases

Monday, August 5, 2013

Teijin Pharma has entered into a collaborative agreement with Amgen to discover, develop and commercialize small molecule drugs that target RORγ. The agreement grants Amgen an option to obtain a worldwide (excluding Japan) exclusive license to compounds discovered in the joint research collaboration, while Teijin Pharma will hold exclusive rights in Japan. Teijin Pharma will also have the right to co-promote potential products in select Asian markets.

[Read More]